The AJMC® Ophthalmology compendium is a comprehensive resource for clinical news and expert insights for treatment of disorders of the eye.
November 26th 2025
Pigment epithelial detachment and hyperreflective foci had better early control in age-related macular degeneration (AMD) when treated with faricimab.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
1 Credit / Cardiology, Neurology
View More
The Evolving Strategies for Managing nAMD and DME: Empowering Managed Care Decisions for Improved Patient Outcomes
1.5 Credits / Endocrinology, Diabetes & Metabolism, Ophthalmology/Optometry
View More
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
View More
Harnessing Data-Driven Insights and Innovations to Enhance AMD and DME Management: Strategic Approaches for Managed Care
1.5 Credits / Ophthalmology/Optometry
View More
Advancing Care in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Optimizing Outcomes With Emerging Therapies
1.5 Credits / Ophthalmology/Optometry
View More
Leveraging Novel Therapies to Transform Demodex Blepharitis Care (Pharmacy Technician Credit)
1.5 Credit / Ophthalmology/Optometry
View More
Leveraging Novel Therapies to Transform Demodex Blepharitis Care
1.5 Credit / Ophthalmology/Optometry
View More
Dr Byron Lam Highlights Treatments in the Pipeline for Inherited Retinal Disease
June 26th 2023Gene therapy is only one exciting area of treatments in the pipeline to potentially treat inherited retinal disease, said Byron L. Lam, MD, professor of ophthalmology, University of Miami Miller School of Medicine's Bascom Palmer Eye Institute.
Watch
Dr Byron Lam Reviews Current Treatments and Therapies in the Pipeline for Inherited Retinal Disease
June 11th 2023The most exciting treatment for inherited retinal disease was approved in 2017, but there are many novel treatments in phase 2 or phase 3 trials at this point, said Byron L. Lam, MD, professor of ophthalmology, University of Miami Miller School of Medicine's Bascom Palmer Eye Institute.
Watch
Dr Byron Lam Discusses Impact on SES Factors on Glaucoma Screening Follow-up
May 29th 2023Insurance is by far the most important factor of whether patients followed up with treatment after getting screened for glaucoma, said Byron L. Lam, MD, professor of ophthalmology, University of Miami Miller School of Medicine's Bascom Palmer Eye Institute.
Watch
Dr Charles Wykoff: Gene Therapy for Wet AMD Would Be a Tremendous Opportunity
May 21st 2023Gene therapies like RGX-314 are looking to treat very common diseases in ophthalmology, which would represent a tremendous opportunity for chronic disease management, said Charles C. Wykoff, MD, PhD, of Retina Consultants of Texas and the Blanton Eye Institute at Houston Methodist Hospital.
Watch
There is a concerted effort to identify biomarkers to understand the risk of progression of diabetic eye disease, but many studies have not been performed in diverse populations, explained Jennifer K. Sun, MD, MPH, associate professor of ophthalmology and chief of the Center for Clinical Eye Research and Trials, Harvard Medical School; and chair, DRCR Retina Network.
Watch
AI Cannot Assist in Prepping for Ophthalmology Board Certification Exams, Study Finds
May 3rd 2023When presented with a set of multiple choice questions used to help trainees practice for the ophthalmology board certification exams, the artificial intelligence (AI) chatbot ChatGPT was able to answer only half correctly.
Read More
Dr Jennifer Sun Highlights Ongoing Research on Preventive Strategies for Diabetic Eye Disease
May 1st 2023The DRCR Retina Network is undertaking research to develop preventive strategies for diabetic eye disease, explained Jennifer K. Sun, MD, MPH, associate professor of ophthalmology and chief of the Center for Clinical Eye Research and Trials, Harvard Medical School; and chair, DRCR Retina Network.
Watch
Dr Charles Wykoff Discusses Gene Therapy to Treat Wet Age-Related Macular Degeneration
April 23rd 2023Gene therapy has the promise of being one and done, but it isn’t always that way for all patients, which leaves questions about where these therapies fit in the commercial landscape, said Charles C. Wykoff, MD, PhD, of Retina Consultants of Texas and the Blanton Eye Institute at Houston Methodist Hospital.
Watch